View in EDS HTML Full Text PDF Full Text

Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.

Saved in:
Bibliographic Details
Title: Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
Authors: Capdevila J; Gastrointestinal and Endocrine Tumor Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), IOB Quiron-Teknon, Barcelona, Spain., Krajewska J; Department of Nuclear Medicine and Endocrine Oncology, Maria Skłodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland., Hernando J; Vall d'Hebron University Hospital, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain., Robinson B; Department of Medicine, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia., Sherman SI; Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jarzab B; Department of Nuclear Medicine and Endocrine Oncology, Maria Skłodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland., Lin CC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Vaisman F; Department of Endocrinology, Instituto Nacional de Câncer, Rio de Janeiro, Brazil., Hoff AO; Department of Endocrinology, Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil., Hitre E; Department of Medical Oncology, The Multidisciplinary Head and Neck Cancer Center, Országos Onkológiai Intézet, Budapest, Hungary., Bowles DW; Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Williamson D; Department of Biostatistics, Exelixis, Inc., Alameda, California, USA., Levytskyy R; Department of Medical Affairs, Exelixis, Inc., Alameda, California, USA., Oliver J; Department of Clinical Development, Exelixis, Inc., Alameda, California, USA., Keam B; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea., Brose MS; Department of Medical Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Source: Thyroid : official journal of the American Thyroid Association [Thyroid] 2024 Mar; Vol. 34 (3), pp. 347-359. Date of Electronic Publication: 2024 Jan 23.
Publication Type: Randomized Controlled Trial; Journal Article
Journal Info: Publisher: Mary Ann Liebert Publishers Country of Publication: United States NLM ID: 9104317 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-9077 (Electronic) Linking ISSN: 10507256 NLM ISO Abbreviation: Thyroid Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38062732
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Capdevila+J%22">Capdevila J</searchLink>; Gastrointestinal and Endocrine Tumor Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), IOB Quiron-Teknon, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Krajewska+J%22">Krajewska J</searchLink>; Department of Nuclear Medicine and Endocrine Oncology, Maria Skłodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland.<br /><searchLink fieldCode="AU" term="%22Hernando+J%22">Hernando J</searchLink>; Vall d'Hebron University Hospital, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Robinson+B%22">Robinson B</searchLink>; Department of Medicine, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Sherman+SI%22">Sherman SI</searchLink>; Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Jarzab+B%22">Jarzab B</searchLink>; Department of Nuclear Medicine and Endocrine Oncology, Maria Skłodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland.<br /><searchLink fieldCode="AU" term="%22Lin+CC%22">Lin CC</searchLink>; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Vaisman+F%22">Vaisman F</searchLink>; Department of Endocrinology, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.<br /><searchLink fieldCode="AU" term="%22Hoff+AO%22">Hoff AO</searchLink>; Department of Endocrinology, Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil.<br /><searchLink fieldCode="AU" term="%22Hitre+E%22">Hitre E</searchLink>; Department of Medical Oncology, The Multidisciplinary Head and Neck Cancer Center, Országos Onkológiai Intézet, Budapest, Hungary.<br /><searchLink fieldCode="AU" term="%22Bowles+DW%22">Bowles DW</searchLink>; Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.<br /><searchLink fieldCode="AU" term="%22Williamson+D%22">Williamson D</searchLink>; Department of Biostatistics, Exelixis, Inc., Alameda, California, USA.<br /><searchLink fieldCode="AU" term="%22Levytskyy+R%22">Levytskyy R</searchLink>; Department of Medical Affairs, Exelixis, Inc., Alameda, California, USA.<br /><searchLink fieldCode="AU" term="%22Oliver+J%22">Oliver J</searchLink>; Department of Clinical Development, Exelixis, Inc., Alameda, California, USA.<br /><searchLink fieldCode="AU" term="%22Keam+B%22">Keam B</searchLink>; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Brose+MS%22">Brose MS</searchLink>; Department of Medical Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229104317%22">Thyroid : official journal of the American Thyroid Association</searchLink> [Thyroid] 2024 Mar; Vol. 34 (3), pp. 347-359. <i>Date of Electronic Publication: </i>2024 Jan 23.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Randomized Controlled Trial; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Mary+Ann+Liebert+Publishers%22">Mary Ann Liebert Publishers </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9104317 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1557-9077 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210507256%22">10507256 </searchLink><i>NLM ISO Abbreviation: </i>Thyroid <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38062732
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1089/thy.2023.0463
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 347
    Titles:
      – TitleFull: Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Capdevila J
      – PersonEntity:
          Name:
            NameFull: Krajewska J
      – PersonEntity:
          Name:
            NameFull: Hernando J
      – PersonEntity:
          Name:
            NameFull: Robinson B
      – PersonEntity:
          Name:
            NameFull: Sherman SI
      – PersonEntity:
          Name:
            NameFull: Jarzab B
      – PersonEntity:
          Name:
            NameFull: Lin CC
      – PersonEntity:
          Name:
            NameFull: Vaisman F
      – PersonEntity:
          Name:
            NameFull: Hoff AO
      – PersonEntity:
          Name:
            NameFull: Hitre E
      – PersonEntity:
          Name:
            NameFull: Bowles DW
      – PersonEntity:
          Name:
            NameFull: Williamson D
      – PersonEntity:
          Name:
            NameFull: Levytskyy R
      – PersonEntity:
          Name:
            NameFull: Oliver J
      – PersonEntity:
          Name:
            NameFull: Keam B
      – PersonEntity:
          Name:
            NameFull: Brose MS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2024 Mar
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1557-9077
          Numbering:
            – Type: volume
              Value: 34
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Thyroid : official journal of the American Thyroid Association
              Type: main
ResultId 1